Rocket Pharmaceuticals (RCKT) Net Cash Flow (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Net Cash Flow data on file, last reported at -$27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 75.45% year-over-year to -$27.9 million; the trailing twelve-month figure through Mar 2026 stood at -$221000.0 (down 101.52% YoY), and the FY2025 full-year result was -$86.1 million, down 179.93% from the prior year.
• Net Cash Flow slipped to -$27.9 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $180.6 million in Q3 2023 to a low of -$169.8 million in Q4 2023.
• A 5-year average of -$10.8 million and a median of -$17.0 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 1877.56% in 2023 and tumbled 610.0% in 2025, its largest moves.
• Tracing RCKT's Net Cash Flow over 5 years: stood at -$56.2 million in 2022, then sank by 202.23% to -$169.8 million in 2023, then surged by 157.75% to $98.0 million in 2024, then tumbled by 98.38% to $1.6 million in 2025, then slumped by 1863.22% to -$27.9 million in 2026.
• Business Quant data shows RCKT's Net Cash Flow at -$27.9 million in Q1 2026, $1.6 million in Q4 2025, and $43.1 million in Q3 2025.